|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-4-18
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The pemetrexed/platinum agent combination represents the standard of care in first-line treatment for malignant pleural mesothelioma (MPM). However, there are no established indicators of responsiveness that can be used to optimize the treatment. This retrospective study aimed to assess the role of excision repair cross-complementing group-1 (ERCC1) and thymidylate synthase (TS) in tumors, and correlate expression levels and polymorphisms of these key determinants of drug activity with the outcome of MPM patients treated with carboplatin/pemetrexed in first-line setting. Experimental design: Analysis of TS and ERCC1 polymorphisms, mRNA and protein expression was done by PCR and immunohistochemistry [with the H-score (histologic score)] in tumor specimens from 126 MPM patients, including 99 carboplatin-/pemetrexed-treated patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BruzzoneAndreaA,
pubmed-author:CeresoliGiovanni LucaGL,
pubmed-author:De VincenzoFabioF,
pubmed-author:DestroAnnaritaA,
pubmed-author:GianoncelliLetiziaL,
pubmed-author:GiordanoLauraL,
pubmed-author:GiovannettiElisaE,
pubmed-author:LorenziElenaE,
pubmed-author:MencoboniManlioM,
pubmed-author:PerrinoMatteoM,
pubmed-author:PetersGodefridus JGJ,
pubmed-author:RoncalliMassimoM,
pubmed-author:SantoroArmandoA,
pubmed-author:SimonelliMatteoM,
pubmed-author:ThunnissenErikE,
pubmed-author:TunesiGianniG,
pubmed-author:ZucaliPaolo AndreaPA
|
|
pubmed:copyrightInfo |
©2011 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2581-90
|
|
pubmed:meshHeading |
pubmed-meshheading:21262916-Adult,
pubmed-meshheading:21262916-Aged,
pubmed-meshheading:21262916-Aged, 80 and over,
pubmed-meshheading:21262916-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21262916-Carboplatin,
pubmed-meshheading:21262916-DNA-Binding Proteins,
pubmed-meshheading:21262916-Endonucleases,
pubmed-meshheading:21262916-Female,
pubmed-meshheading:21262916-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21262916-Gene Frequency,
pubmed-meshheading:21262916-Genotype,
pubmed-meshheading:21262916-Glutamates,
pubmed-meshheading:21262916-Guanine,
pubmed-meshheading:21262916-Humans,
pubmed-meshheading:21262916-Immunohistochemistry,
pubmed-meshheading:21262916-Male,
pubmed-meshheading:21262916-Mesothelioma,
pubmed-meshheading:21262916-Middle Aged,
pubmed-meshheading:21262916-Multivariate Analysis,
pubmed-meshheading:21262916-Pleural Neoplasms,
pubmed-meshheading:21262916-Polymorphism, Single Nucleotide,
pubmed-meshheading:21262916-Prognosis,
pubmed-meshheading:21262916-Retrospective Studies,
pubmed-meshheading:21262916-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:21262916-Survival Analysis,
pubmed-meshheading:21262916-Thymidylate Synthase,
pubmed-meshheading:21262916-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
|
|
pubmed:affiliation |
Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy. paolo.zucali@humanitas.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
